Rhythm Biosciences Advances ColoSTAT® and Expands Product Portfolio

Rhythm Biosciences Ltd. ( (AU:RHY) ) has provided an announcement.

Rhythm Biosciences Ltd has announced significant progress in its ColoSTAT® Beta kits, which are in the final verification phase and preparing for clinical validation. The company has also successfully integrated the Genetype business and relaunched the geneType™ product portfolio, achieving its first commercial sales. These developments, alongside strategic management enhancements, position Rhythm Biosciences to strengthen its operations and market presence, with expectations for further milestones in the upcoming quarters.

More about Rhythm Biosciences Ltd.

Rhythm Biosciences Ltd is a transformative, predictive cancer diagnostics technology company focused on supporting individuals in managing their health through cancer risk assessment, disease detection, and therapy management. The company is particularly focused on developing new methods for early disease detection, especially for cancers like bowel cancer, which are often detected outside recommended screening programs.

YTD Price Performance: -15.56%

Average Trading Volume: 259,613

Technical Sentiment Signal: Strong Buy

Current Market Cap: A$22.03M

Find detailed analytics on RHY stock on TipRanks’ Stock Analysis page.